Lv3
296 积分 2024-03-14 加入
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
1个月前
已完结
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia
1个月前
已完结
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
1个月前
已完结
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
1个月前
已完结
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
1个月前
已完结
How I treat T-cell chronic active Epstein-Barr virus disease
1个月前
已完结
Non-Hodgkin lymphoma
2个月前
已关闭
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
2个月前
已完结
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
2个月前
已完结
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
2个月前
已完结
皖公网安备34019202002308
